Du är här

2014-04-09

Basilea Pharmaceutica AG: Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.

Basilea Pharmaceutica AG / Resolutions of the Ordinary General Meeting of
Shareholders of BasileaPharmaceutica Ltd. . Processed and transmitted by
NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
Basel, Switzerland, April 9, 2014

-Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that at today's Ordinary
General Meeting of Shareholders for the financial year 2013, shareholders
approved all agenda items proposed by the Board of Directors. At the meeting,
51.3 percent of Basilea's share capital was represented.

The shareholders approved the annual report, the financial statements and
consolidated financial statements for the business year 2013, and released
the members of the Board of Directors and the Management Committee.
Shareholders also approved carrying forward the accumulated deficit and
re-elected PricewaterhouseCoopers AG, Basel as Statutory Auditors for the
audit of the stand-alone and the consolidated financial statements for the
business year 2014.

In addition, the shareholders approved the Board of Directors' proposal to
amend the Articles of Incorporation ("Articles") in order to implement the
Ordinance Against Excessive Compensation in Listed Companies, as well as the
Board's other proposals for amendment of the Articles.

All current members of Basilea's Board of Directors were re-elected: Dr.
Martin Nicklasson, Domenico Scala, Hans-Beat Gürtler, Prof. Daniel Lew, Dr.
Thomas M. Rinderknecht, Steven D. Skolsky and Dr. Thomas Werner. Dr.
Nicklasson was elected as the Chairman of the Board of Directors. The
shareholders also elected Dr. Nicklasson, Mr. Skolsky and Dr. Werner as
members of the Compensation Committee. Dr. Caroline Cron was elected as
Independent Voting Rights Representative. The terms of all these individuals
last until the end of the 2015 Ordinary General Meeting of Shareholders.

Finally, the shareholders approved the creation of Authorized Share Capital to
provide Basilea with the flexibility to quickly respond to strategic
opportunities. The authorization is valid for a period of two years.

In his presentation to shareholders, Chief Executive Officer Ronald Scott
highlighted: "2013 was a very successful year for Basilea. We achieved key
milestones including the approval of our antibiotic ceftobiprole in Europe
and presented positive Phase 3 topline results for the antifungal
isavuconazole. We are anticipating further significant milestones in 2014
such as the planned filing of isavuconazole in Europe and the U.S. as well as
the launch of ceftobiprole in first key European countries. Basilea will
continue to move forward to deliver life-saving drugs to patients and bring
the company to sustainable profitability."

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed
on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research
and development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd., the company focuses on innovative pharmaceutical products
in the therapeutic areas of bacterial infections, fungal infections and
oncology, targeting the medical challenge of rising resistance and
non-response to current treatment options.

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Basilea Pharmaceutica Ltd. to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.

For further information, please contact:

-------------------------------------------------------------
|Media Relations Investor Relations |
|Peer Nils Schröder, PhD Barbara Zink, PhD, MBA |
| |
|Head Public Relations& Head Corporate Development |
|Corporate Communications |
|+41 61 606 1102 +41 61 606 1233 |
|media_relations@basilea.com investor_relations@basilea.com |
-------------------------------------------------------------
This press release can be downloaded fromwww.basilea.com.

Press release (PDF)
http://hugin.info/134390/R/1776105/605886.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Globenewswire

HUG#1776105

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.